# Australasian Gastro-Intestinal Trials Group

Source: https://onco.cc/companies/agitg/  
OnCo record `agitg` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Australia and New Zealand's gastrointestinal cancer trials group, running practice-informing trials in gastric, oesophageal, colorectal and pancreatic cancer, including ctDNA-guided adjuvant studies.

## Summary

Founded in 1991, AGITG (operating publicly as the GI Cancer Institute) designs and runs investigator-initiated trials across Australia, New Zealand and international partners, with the NHMRC Clinical Trials Centre as its coordinating centre. TOPGEAR tested preoperative chemoradiotherapy in gastric cancer, INTEGRATE established regorafenib activity in refractory gastro-oesophageal cancer, and ASCOLT tested aspirin after colorectal cancer surgery. DYNAMIC-III extends the Australian ctDNA-guided adjuvant programme that began with the DYNAMIC study into stage III colon cancer. AGITG also runs hepatocellular, biliary and neuroendocrine tumour trials and partners with TROG and ANZUP.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: AGITG; GI Cancer Institute
- Tags: cooperative-group
- HQ: Sydney
- Type: cooperative-group
- Website: https://gicancer.org.au

## Notes

- TOPGEAR (gastric chemoradiotherapy)
- INTEGRATE (regorafenib)
- DYNAMIC-III (ctDNA-guided adjuvant therapy)
- ASCOLT (aspirin after colorectal surgery)

## Sources

- GI Cancer Institute / AGITG: https://gicancer.org.au
- Clinical trials: https://gicancer.org.au/clinical-trials/

## Connected records

- trials: [DYNAMIC](https://onco.cc/trials/dynamic/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [ANZUP Cancer Trials Group](https://onco.cc/companies/anzup/), [TROG Cancer Research](https://onco.cc/companies/trog/)
- institutions: [Cancer Council Australia](https://onco.cc/institutions/cancer-council-australia/), [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- people: [Christos Karapetis](https://onco.cc/people/christos-karapetis/), [Geoff Parnell](https://onco.cc/people/geoff-parnell/)

---
JSON: https://onco.cc/api/v1/entities/agitg.json